- Home
- DOUG vs PBYI Comparison
DOUG vs PBYI Comparison
Compare DOUG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | PBYI |
|---|---|---|
| Founded | 1911 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 467.2M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | DOUG | PBYI |
|---|---|---|
| Price | $1.52 | $9.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 467.6K | 247.3K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $955,578,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.33 |
| P/E Ratio | ★ N/A | $123.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $4.58 |
| 52 Week High | $3.03 | $9.98 |
Technical Indicators
Market Signals| Indicator | DOUG | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 58.06 |
| Support Level | N/A | $8.90 |
| Resistance Level | $1.82 | $9.98 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 21.43 | 71.30 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.